Navigation Links
Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
Date:5/7/2013

(PRWEB) May 07, 2013

Drug manufacturer Merck recently sought and earned U.S. Food and Drug Administration approval for a new drug that pairs its own cholesterol-lowering Zetia with a generic version of Lipitor, the blockbuster statin marketed by Pfizer before it lost patent protection in 2011. The Rottenstein Law Group, which represents clients in Lipitor lawsuits, is watching this development closely, noting that studies have established a link between Lipitor and Type 2 diabetes.

The new drug, Liptruzet, is found to lower cholesterol but does not lower the risk for cardiovascular disease, according to a May 3 New York Times article.* Despite Lipitor’s popularity** there is at least one study that shows it has its own share of risks. According to a study in the January 2012 edition of JAMA: Internal Medicine, there is a potential link between statins and a Type 2 diabetes risk in women.***

“The FDA makes regulatory choices every day, but this one is troubling,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “This is especially true when considering the side effects we hear about daily from clients, in addition to the impact these choices can have on Lipitor lawsuits.”

Prompted by the drug’s potentially serious side effects, plaintiffs across the nation are filing Lipitor lawsuits, many under consideration for consolidation into a multidistrict litigation (In re Lipitor (Atorvastatin) Litigation, MDL No. 2459 (JPML)).

The Rottenstein Law Group operates the Lipitor Lawsuit Information Center. This page on the firm’s website includes a comprehensive look at Lipitor side effects and how to contact an attorney to determine if Lipitor patients are able to file a lawsuit.

*nytimes.com/2013/05/04/business/fda-approves-mercks-combination-drug-to-reduce-cholesterol.html?_r=0

**bloomberg.com/news/2013-04-30/pfizer-lowers-2013-forecast-after-sales-miss-analyst-estimates.html

***archinte.jamanetwork.com/article.aspx?articleid=1108676

About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and drugs. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group, LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
http://www.rotlaw.com

                            ###

Read the full story at http://www.prweb.com/releases/side-effects-lipitor/lipitor-recall/prweb10706791.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lipitor Diabetes Lawsuit Filed by South Carolina Woman Who Developed Type 2 Diabetes Allegedly Due to Lipitor Use, Alonso Krangle Investigating
2. New Lawsuit on Serious Birth Defects from Depakote: Now, AttorneyOne Can Provide Advice
3. Texas Woman Alleges Actos Caused her Bladder Cancer, Parker Waichman LLP Files Lawsuit on Victim’s Behalf
4. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
5. Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Protective Order in Federal C.R. Bard Vaginal Mesh Litigation, Bernstein Liebhard LLP Reports
6. Smith & Nephew Hip Recall News: Bernstein Liebhard LLP Notes Motion to Consolidate Smith & Nephew Lawsuits Filed in Tennessee State Courts
7. Stryker Hip Recall Lawsuits Stemming from Rejuvenate and ABG II Hip Stem Recall Continue to Mount in New Jersey Litigation
8. Imprelis Lawsuit Filed on Behalf of Indiana Country Club, Alleging That Imprelis Use Seriously Damaged the Club’s Landscape and Profits, Reports Wright & Schulte
9. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Actos Bladder Cancer Litigation
10. Pradaxa Lawsuits Move Forward, With Scheduling of Next Status Conference in Federal Pradaxa Litigation, Bernstein Liebhard LLP Reports
11. Alleged DePuy Knee Sleeve Failure Lawsuits Now Being Reviewed by Resource4thePeople Attorneys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... 2016 , ... Global Lyme Alliance (GLA), a leading nonprofit ... has named Scott Santarella as its new CEO. , Santarella is former ... San Francisco, where he successfully helped to grow the organization from a regional ...
(Date:5/24/2016)... ... May 24, 2016 , ... Researchers ... of protocols designed to reduce bleeding complications from percutaneous coronary intervention (PCI). The ... Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted bleeding event ...
(Date:5/24/2016)... ... May 24, 2016 , ... Design Concepts ... ‘El Centro del Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was ... offer something special for this often overlooked neighborhood. Located at 609 E. 6th ...
(Date:5/24/2016)... ... May 24, 2016 , ... Celebration is in ... kicked off its 5th Annual Photo Contest. The label contest is underway, and ... year's prizes include a GoPro Hero4, a 40-inch high-definition flat-screen television, an Apple ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... On the ... took the time to summarize the weight loss process: , New patients have a ... Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There are 15 ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... , May 23, 2016 The ... USD 5.0 billion by 2022, according to a new ... of medical waste coupled with the lack of centralized ... expected to drive the demand for reprocessed medical devices ... as compared to that of the original device is ...
(Date:5/22/2016)... DUBLIN , May 23, 2016 ... to develop its anti-fibrotic and anti-inflammatory compound DS102 ... well as in non-alcoholic steatohepatitis (NASH) patients. ... is significantly sequestered in lung tissue and has ... tissue after oral administration. The Company will publish ...
Breaking Medicine Technology: